Company profile
C4 Therapeutics, Inc.
NASDAQ:CCCCBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Sendegobresib | phase1 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05355753 | phase1 | terminated | 2022-03-25 | 2023-12-19 | C4 Therapeutics, Inc. | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors |
| NCT05668585 | phase1 | completed | 2022-12-08 | 2025-11-05 | C4 Therapeutics, Inc. | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors |
| NCT07284758 | phase2 | recruiting | 2026-02-18 | 2030-03-01 | C4 Therapeutics, Inc. | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma |
| NCT07280013 | phase1 | recruiting | 2026-02-06 | 2028-12-01 | C4 Therapeutics, Inc. | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects |
| NCT04756726 | phase1 | active_not_recruiting | 2021-04-27 | 2026-09-30 | C4 Therapeutics, Inc. | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma |
FDA applications (0)
No records yet.